Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| InMed Pharmaceuticals Inc.INM · Entity 8139 | Director | December 19, 2025 | December 19, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
InMed Pharmaceuticals Inc.
Report date December 19, 2025 · Filed December 19, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.29 · Expires 2030-12-18 | Direct | 2,711 |
Reported balance
After 2025-12-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-12-19 · Grant · Acquired 1,750 · Balance 2,711 F1: The options were granted on 12/19/2025 and will vest 100% on the one-year anniversary of the grant date (December 18, 2026) or immediately prior to the next Annual General Meeting, whichever is sooner. |
Filing footnotes · ownership attribution and instrument terms
F1: The options were granted on 12/19/2025 and will vest 100% on the one-year anniversary of the grant date (December 18, 2026) or immediately prior to the next Annual General Meeting, whichever is sooner.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 19, 2025 Filed Dec 19, 2025 11:38 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | GrantEmployee Stock Option (Right to Buy) · Derivative | 1,750 | $0.00 Strike: $1.29 | $0.00 |
DisclosureSEC source: 0001213900-25-123620 · ownership.xml · derivative · entry 1 HULL ANDREW · CIK 0001818252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,711 Underlying: Common shares · 1,750 shares Expires 2030-12-18 F1 · derivative.exercise_date: The options were granted on 12/19/2025 and will vest 100% on the one-year anniversary of the grant date (December 18, 2026) or immediately prior to the next Annual General Meeting, whichever is sooner. Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 12:20 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | OtherEmployee Stock Option (Expiration) · Derivative | 14 | $0.00 Strike: $1,397.97 | $0.00 |
DisclosureSEC source: 0001213900-25-122649 · ownership.xml · derivative · entry 1 HULL ANDREW · CIK 0001818252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 961 Underlying: Common shares · 14 shares Expires 2025-12-15 F1 · derivative.exercise_price: Converted from the Canadian dollar exercise price of C$1,925.00 using an exchange rate of C$1.3770 = $US1.00 Read SEC document |
| January 11, 2025 Filed Feb 3, 2025 08:49 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | OtherEmployee Stock Option (Expiration) · Derivative | 2 | $0.00 Strike: $2,860.21 | $0.00 |
DisclosureSEC source: 0001213900-25-009136 · ownership.xml · derivative · entry 1 HULL ANDREW · CIK 0001818252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 975 Underlying: Common shares · 2 shares Expires 2025-01-11 F1 · derivative.exercise_price: Converted from the Canadian dollar exercise price of C$4,125.00 using an exchange rate of C$1.4422 = $US1.00 Read SEC document |
| December 20, 2024 Filed Dec 23, 2024 09:17 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | GrantEmployee Stock Option (Right to Buy) · Derivative | 550 | $0.00 Strike: $4.14 | $0.00 |
DisclosureSEC source: 0001213900-24-111543 · ownership.xml · derivative · entry 1 HULL ANDREW · CIK 0001818252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 977 Underlying: Common shares · 550 shares Expires 2029-12-19 F1 · derivative.exercise_date: The options were granted on 12/20/2024 and will vest 100% on the one-year anniversary of the grant date (December 19, 2025) or immediately prior to the next Annual General Meeting, whichever is sooner. F2 · balance_after: On November 14, 2024, the common stock of InMed was reverse split on a 1-for-20 basis. This number reflects that reverse stock split. Read SEC document |
| February 21, 2024 Filed Feb 22, 2024 13:38 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | PurchaseCommon Stock | 37,500 | $0.39 | $14,625.00 |
DisclosureSEC source: 0001213900-24-016026 · ownership.xml · nonDerivative · entry 1 HULL ANDREW · CIK 0001818252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,258 Read SEC document |
| January 14, 2024 Filed Mar 5, 2024 15:20 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | OtherEmployee Stock Option (Expiration) · Derivative | 42 | $0.00 Strike: $307.01 | $0.00 |
DisclosureSEC source: 0001213900-24-020088 · ownership.xml · derivative · entry 1 HULL ANDREW · CIK 0001818252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,542 Underlying: Common shares · 42 shares Expires 2024-01-14 F1 · derivative.exercise_price: Converted from the Canadian dollar exercise price of C$412.50 using an exchange rate of C$1.3436 = $US1.00 Read SEC document |
| December 23, 2023 Filed Dec 26, 2023 13:04 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | GrantEmployee Stock Option (Right to Buy) · Derivative | 7,100 | $0.00 Strike: $0.37 | $0.00 |
DisclosureSEC source: 0001213900-23-098486 · ownership.xml · derivative · entry 1 HULL ANDREW · CIK 0001818252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,584 Underlying: Common shares · 7,100 shares Expires 2028-12-22 F1 · derivative.exercise_date: The options were granted on 12/23/2023 and will vest 100% on the one-year anniversary of the grant date (December 23, 2024) or immediately prior to the next Annual General Meeting, whichever is sooner. Read SEC document |
| December 16, 2022 Filed Dec 19, 2022 16:51 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | GrantEmployee Stock Option (Right to Buy) · Derivative | 840 | $0.00 Strike: $1.78 | $0.00 |
DisclosureSEC source: 0001213900-22-080959 · ownership.xml · derivative · entry 1 HULL ANDREW · CIK 0001818252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,484 Underlying: Common shares · 840 shares Expires 2027-12-15 F1 · derivative.exercise_date: The options were granted on 12/16/2022 and will vest as follows: Vesting 100% on the one-year anniversary of the grant date (Dec 16, 2023) or immediately prior to the next AGM, whichever is sooner. F2 · balance_after: On September 7, 2022, the common stock of InMed was reverse split on a 1-for-25 basis. This number reflects that reverse stock split. Read SEC document |
| January 24, 2022 Filed Jan 24, 2022 16:17 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | OtherEmployee Stock Option (Expiration) · Derivative | 30,303 | $0.00 Strike: $2.89 | $0.00 |
DisclosureSEC source: 0001213900-22-003331 · ownership.xml · derivative · entry 1 HULL ANDREW · CIK 0001818252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,122 Underlying: Common shares · 30,303 shares Expires 2022-01-24 F1 · derivative.exercise_price: Converted from the Canadian dollar exercise price of C$3.63 using an exchange rate of C$1.2554 = $US1.00 Read SEC document |
| December 29, 2021 Filed Dec 30, 2021 18:02 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | GrantEmployee Stock Option (Right to Buy) · Derivative | 7,000 | $0.00 Strike: $1.32 | $0.00 |
DisclosureSEC source: 0001213900-21-068184 · ownership.xml · derivative · entry 1 HULL ANDREW · CIK 0001818252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,425 Underlying: Common shares · 7,000 shares Expires 2026-12-28 F1 · derivative.exercise_date: The options were granted on 12/29/2021 and will vest 100% on the one year anniversary of the grant date (Dec 29, 2022) or immediately prior to the next AGM, whichever is sooner. Read SEC document |
| December 16, 2020 Filed Dec 18, 2020 06:20 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | GrantEmployee Stock Option (Right to Buy) · Derivative | 7,000 | $0.00 Strike: $3.02 | $0.00 |
DisclosureSEC source: 0001213900-20-043366 · ownership.xml · derivative · entry 1 HULL ANDREW · CIK 0001818252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Underlying: Common shares · 7,000 shares Expires 2025-12-15 F1 · derivative.exercise_price: The Canadian exercise price of C$3.85 was converted into U.S. dollars using an exchange rate of C$1.2753 = US$1.00. F2 · derivative.exercise_date: The options were granted on 12/16/2020 and will vest 100% on the one year anniversary of the grant date (Dec 16, 2021) or immediately prior to the next AGM, whichever is sooner. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.